ASAnna-Lea T. Stalder

Anna-Lea T. Stalder

*This is an algorithmically generated author record based on publicly available information.

Anna-Lea T. Stalder has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Haptoglobin and Hemopexin Redirect Heme-Driven Oxidative Stress and Neurotoxicity in Organotypic Brain Slices

    by Anna-Lea T. Stalder, Raphael M. Buzzi, Florence Vallelian, Dominik J. Schaer

    Hemorrhagic stroke triggers secondary brain injury through the red blood cell toxins hemoglobin (Hb) and heme, which fuel iron-driven lipid peroxidation and neuronal injury. We sought to use organotypic brain-slice cultures to dissect how the high-affinity scavenger proteins haptoglobin (Hp) and hemopexin (Hpx) modulate this cascade. By day 7 of culture, slices remained structurally intact, metabolically active, and responsive to oxidative stress, enabling precise toxin exposure studies. Isotopic 58Fe tracing revealed that upon cell-free Hb and heme exposures, heme-iron accumulated in brain slices and heightened lipid peroxidation. In contrast, Hpx neutralized heme, nearly abolishing iron deposition, while Hp partially reduced Hb-driven iron accumulation. Both scavengers attenuated lipid peroxidation and reduced neuronal cell death. Transcriptomic profiling revealed that free toxins increased oxidative stress and neuroinflammatory activation markers, whereas Hpx suppressed the expression of heme-induced genes. Remarkably, HbHp complexes triggered a strong Nrf2-centered adaptive program that enhanced iron metabolism and glutathione synthesis. Integrating five readouts─iron accumulation, lipid peroxidation, neuronal cell death, heme-stress transcripts, and Nrf2/metabolic transcripts─via bootstrap-based principal component analysis yielded two orthogonal axes. An oxidative toxicity axis (PC1) captured iron-driven reactive oxygen species and cell death, while a metabolic adaptation axis (PC2) reflected Nrf2-mediated reprogramming. Free toxins clustered at the toxic extreme on PC1, and heme-Hpx aligned near baseline. HbHp shifted slices upward on PC2, reducing neuronal loss through safe adaptation. These findings establish that Hpx neutralizes free heme, whereas Hp stabilizes Hb and elicits cytoprotective gene expression, offering a rational, dual-scavenger strategy to mitigate secondary brain injury in hemorrhagic stroke.


  • Open Access

    Systematic Review and Meta-Analysis of 3 Treatment Arms for Vertebral Compression Fractures

    by Sascha Halvachizadeh, Anna-Lea Stalder, David Bellut, Sven Hoppe, Philipp Rossbach, Alessandro Cianfoni, Klaus John Schnake, Ladislav Mica, Roman Pfeifer, Kai Sprengel, et al.

    Background: Osteoporotic vertebral fractures (OVFs) have become increasingly common, and previous nonrandomized and randomized controlled trials (RCTs) have compared the effects of cement augmentation versus nonoperative management on the clinical outcome. This meta-analysis focuses on RCTs and the calculated differences between cement augmentation techniques and nonsurgical management in outcome (e.g., pain reduction, adjacent-level fractures, and quality of life [QOL]). Methods: A systematic review was performed according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, and the following scientific search engines were used: MEDLINE, Embase, Cochrane, Web of Science, and Scopus. The inclusion criteria included RCTs that addressed different treatment strategies for OVF. The primary outcome was pain, which was determined by a visual analog scale (VAS) score; the secondary outcomes were the risk of adjacent-level fractures and QOL (as determined by the EuroQol-5 Dimension [EQ-5D] questionnaire, the Oswestry Disability Index [ODI], the Quality of Life Questionnaire of the European Foundation for Osteoporosis [QUALEFFO], and the Roland-Morris Disability Questionnaire [RDQ]). Patients were assigned to 3 groups according to their treatment: vertebroplasty (VP), kyphoplasty (KP), and nonoperative management (NOM). The short-term (weeks), midterm (months), and long-term (>1 year) effects were compared. A random effects model was used to summarize the treatment effect, including I 2 for assessing heterogeneity and the revised Cochrane risk-of-bias 2 (RoB 2) tool for assessment of ROB. Funnel plots were used to assess risk of publication bias. The log of the odds ratio (OR) between treatments is reported. Results: After screening of 1,861 references, 53 underwent full-text analysis and 16 trials (30.2%) were included. Eleven trials (68.8%) compared VP and NOM, 1 (6.3%) compared KP and NOM, and 4 (25.0%) compared KP and VP. Improvement of pain was better by 1.31 points (95% confidence interval [CI], 0.41 to 2.21; p < 0.001) after VP when compared with NOM in short-term follow-up. Pain effects were similar after VP and KP (midterm difference of 0.0 points; 95% CI, −0.25 to 0.25). The risk of adjacent-level fractures was not increased after any treatment (log OR, −0.16; 95% CI, −0.83 to 0.5; NOM vs. VP or KP). QOL did not differ significantly between the VP or KP and NOM groups except in the short term when measured by the RDQ. Conclusions: This meta-analysis provides evidence in favor of the surgical treatment of OVFs. Surgery was associated with greater improvement of pain and was unrelated to the development of adjacent-level fractures or QOL. Although improvements in sagittal balance after surgery were poorly documented, surgical treatment may be warranted if pain is a relevant problem. Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.